Severe combined immunodeficiency (SCID) caused by adenosine deaminase deficiency (ADA–) is the first genetic disorder to be treated with gene therapy. Since 1990 when the first trial started for 2 patients with ADA– SCID, five clinical trials enrolling 11 patients have been conducted with different clinical approaches and the results obtained from these trials have recently been reported. According to these reports, T cell-directed gene transfer was useful in the treatment of ADA– SCID whereas the retroviral-mediated gene transfer to hematopoietic stem cells was insufficient for achievement of clinical benefits. This chapter reviews several crucial problems inherent in the current retroviral technology based on the clinical data observed in these pioneering ADA gene therapy trials and presents our new retroviral vector system for the next stem cell gene therapy.

Keywords:
Gene therapy, Retroviral vector, Severe combined immunodeficiency, adenosine deaminase, Stem cells, hematopoietic, T lymphocytes, peripheral
1.
Mulligan RC: The basic science of gene therapy. Science 1993;260:926–932.
2.
Joyner A, Keller G, Phillips RA, Bernstein A: Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells. Nature 1983;305:556–558.
3.
Bodine DM, McDonagh KT, Seidel NE, Nienhuis AW: Survival and retrovirus infection of murine hematopoietic stem cells in vitro: Effects of 5-FU and method of infection. Exp Hematol 1991;19:206–212.
4.
Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WR: T lymphocyte-directed gene therapy for ADA– SCID: Initial trial results after 4 years. Science 1995;270:475–480.
5.
Dunbar CE, Cottler-Fox M, O’Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson WH, Cowan K, Young NS, Nienhuis AW: Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85:3048–3057.
6.
Havenga M, Hoogerbrugge P, Valerio D, van Es HH: Retroviral stem cell gene therapy. Stem Cells 1997;15:162–179.
7.
Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216–223.
8.
Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT Jr, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC: Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med 1998;4:852–856.
9.
Kredich NM, Hershfield MS: Immunodeficiency disease associated with adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency; in Scriver CM, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, ed 5. New York, McGraw-Hill, 1989, p 1045.
10.
Hirschhorn R: Adenosine deaminase deficiency; in Rosen FS, Seligmann M (eds): Immunodeficiency Reviews. London, Harwood Academic Publications, 1990, vol 2, p 175.
11.
Hershfield MS, Chaffee S, Sorensen RU: Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: Overview and case reports of three patients, including two now receiving gene therapy. Pediatr Res 1993;33(suppl 1):S42–S47.
12.
Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH: Human adenosine deaminase. cDNA and complete primary amino acid sequence. J Biol Chem 1984;259:12101–12106.
13.
Valerio D, McIvor RS, Williams SR, Duyvesteyn MG, van Ormondt H, van der Eb AJ, Martin DW Jr: Cloning of human adenosine deaminase cDNA and expression in mouse cells. Gene 1984;31:147–153.
14.
Wiginton DA, Adrian GS, Hutton JJ: Sequence of human adenosine deaminase cDNA including the coding region and a small intron. Nucleic Acids Res 1984;12:2439–2446.
15.
Wiginton DA, Kaplan DJ, States JC, Akeson AL, Perme CM, Bilyk IJ, Vaughn AJ, Lattier DL, Hutton JJ: Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry 1986;25:8234–8244.
16.
Daddona PE, Mitchell BS, Meuwissen HJ, Davidson BL, Wilson JM, Koller CA: Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. J Clin Invest 1983;72:483–492.
17.
Valentine WN, Paglia DE, Tartaglia AP, Gilsanz F: Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. Science 1977;195:783–785.
18.
Kantoff PW, Gillio AP, McLachlin JR, Bordignon C, Eglitis MA, Kernan NA, Moen RC, Kohn DB, Yu SF, Karson E, Karlsson S, Zwiebel JA, Gilboa E, Blaese RM, Nienhuis A, O’Reilly RJ, Anderson WF: Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer. J Exp Med 1987;166:219–234.
19.
Buckley RH, Schiff SE, Sampson HA, Schiff RI, Markert ML, Knutsen AP, Hershfield MS, Huang AT, Mickey GH, Ward FE: Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol 1986;136:2398–2407.
20.
Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, Tame A, Furuta H, Okano M, Matsumoto S, Kotani H, McGarrity GJ, Blaese RM, Sakiyama Y: Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 1998;91:30–36.
21.
Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P, Ugazio AG, Mavilio F: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA– immunodeficient patients. Science 1995;270:470–475.
22.
Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D: Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 1996;3:179–183.
23.
Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, el-Khoureiy A, Lawrence K, Wells D, Moen RC, Bastian J, Williams-Herman DE, Elder M, Wara D, Bowen T, Hershfield MS, Mullen CA, Blaese RM, Parkman R: Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1995;1:1017–1023.
24.
Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R: T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 1998;4:775–780.
25.
Onodera M, Nelson DM, Yachie A, Jagadeesh GJ, Bunnell BA, Morgan RA, Blaese RM: Development of improved adenosine deaminase retroviral vectors. J Virol 1998;72:1769–1774.
26.
Hock RA, Miller AD, Osborne WR: Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell. Blood 1989;74:876–881.
27.
Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV: Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991;65:2220–2224.
28.
Onodera M, Yachie A, Nelson DM, Welchlin H, Morgan RA, Blaese RM: A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther 1997;8:1189–1194.
29.
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK: High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995;69:7430–7436.
30.
Kohn DB, Mitsuya H, Ballow M, Selegue JE, Barankiewicz J, Cohen A, Gelfand E, Anderson WF, Blaese RM: Establishment and characterization of adenosine deaminase-deficient human T cell lines. J Immunol 1989;142:3971–3977.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.